Contribute Try STAT+ Today

Legend Biotech raised more than $400 million in a Nasdaq IPO on Friday, marking the largest U.S. debut for Chinese drug maker. But Legend’s Wall Street success arrives at an uncertain time for Chinese companies, as a bipartisan group of lawmakers is pushing a bill that could force it and scores of other companies off of U.S. exchanges.

Legend, which is headquartered in Nanjing, priced 18.4 million shares at $23 each. Legend’s most advanced treatment, a CAR-T cancer therapy partnered with Johnson & Johnson, demonstrated impressive results in multiple myeloma in data presented last week.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.